RxDoctor Payments Data

Megan Frank, MD

Family Medicine · Columbus, OHNPI 1821290313

Payments from drug & device makers

$5,610in general payments, 2019–2025

Across 400 payments — averaging $14.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$712
  • AbbVie$507
  • AstraZeneca$346
  • Exact Sciences$282
  • Pfizer$280
  • Amarin Pharma, Inc.$256
  • plus $3K from 49 others

What the payments were for

  • Food & beverage$5,54599%
  • Education$661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,610 in reported general payments places this provider in the 85th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$47,306
Medicare patients
117
Services billed
849

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin51$49,533
OzempicSemaglutide36$43,636
TrulicityDulaglutide30$42,788
EliquisApixaban38$36,939
XareltoRivaroxaban25$28,008
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$23,745
ProliaDenosumab11$18,833
MyrbetriqMirabegron25$17,301
JanuviaSitagliptin Phosphate19$16,454
Bydureon BciseExenatide Microspheres13$15,971
MounjaroTirzepatide15$15,922
VascepaIcosapent Ethyl16$13,646
EntrestoSacubitril/Valsartan11$12,145
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt12$12,077
Breo ElliptaFluticasone/Vilanterol24$12,001

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humalog$249$61,32358 claims
Boehringer IngelheimJardiance$123$49,53351 claims
Novo NordiskOzempic$712$43,63636 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$193$40,57978 claims
PfizerEliquis$280$36,93938 claims
Johnson & JohnsonXarelto$131$28,00825 claims
MerckJanuvia, Belsomra$39$25,01038 claims
AmgenProlia$246$18,83311 claims
Astellas Pharma US IncMyrbetriq$17$17,30125 claims
NovartisEntresto$169$12,14511 claims
AstraZenecaSymbicort$346$7,46220 claims
Sanofi-aventis U.S. LLCAmbien$102$7,07212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →